Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

被引：0
|
作者：
Cree, B. A. [1 ]
Selmaj, K. W. [2 ]
Steinman, L. [3 ]
Comi, G. [4 ]
Bar-Or, A. [5 ]
Arnold, D. L. [6 ]
Hartung, H. [7 ,8 ,9 ]
Montalban, X. [10 ]
Havrdova, E. K. [11 ,12 ]
Sheffield, J. K. [13 ]
Minton, N. [13 ]
Cheng, C. [13 ]
Silva, D. [13 ]
Kappos, L. [14 ,15 ,16 ,17 ,18 ]
Cohen, J. A. [19 ]
机构：
[1] Weill Inst Neurosci, San Francisco, CA USA
[2] Univ Warmia & Mazury, Ctr Neurol & Coll Med, Lodz, Poland
[3] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA 94305 USA
[4] Vita Salute San Raffaele Univ & Casa Cura Policli, Milan, Italy
[5] McGill Univ, Philadelphia, PA USA
[6] Montreal Neurol Inst, Neurol & Neurosurg, Montreal, PQ, Canada
[7] Heinrich Heine Univ, Fac Med, Dept Neurol, Dusseldorf, Germany
[8] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia
[9] Med Univ Vienna, Dept Neurol, Dusseldorf, Germany
[10] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[11] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[12] Charles Univ Prague, Med Fac 1, Ctr Clin Neurosci, Prague, Czech Republic
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Univ Hosp, Dept Med, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[15] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[16] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[17] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[18] Univ Basel, Basel, Switzerland
[19] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P142
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
    Saida T.
    Kira J.-I.
    Kishida S.
    Yamamura T.
    Ohtsuka N.
    Ling Y.
    Torii S.
    Lucas N.
    Kuesters G.
    Steiner D.
    Tibung J.T.
    Neurology and Therapy, 2017, 6 (1) : 39 - 55
  • [32] Design of a multicentre, open-label extension study to evaluate the long-term safety, immunogenicity, anti efficacy of natalizumab in patients with multiple sclerosis
    O'Connor, P
    Toal, M
    Wilmer-Hulme, A
    Yang, M
    Panzara, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S261 - S261
  • [33] Relationship between infections and absolute lymphocyte count during phase 3 and open-label extension trials of ozanimod in patients with relapsing multiple sclerosis
    Hartung, H. -P.
    Steinman, L.
    Bar-Or, A.
    Sheffield, J. K.
    Harris, S.
    Riolo, J. V.
    Cheng, C. -Y.
    Silva, D.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 622 - 622
  • [34] Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James K.
    Harris, Sarah
    Riolo, Jon V.
    Cheng, Chun-Yen
    Silva, Diego
    Cree, Bruce A. C.
    NEUROLOGY, 2023, 100 (17)
  • [35] Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
    Ralf Gold
    Ernst-Wilhelm Radue
    Gavin Giovannoni
    Krzysztof Selmaj
    Eva Kubala Havrdova
    Xavier Montalban
    Dusan Stefoski
    Till Sprenger
    Randy R. Robinson
    Sami Fam
    Jonathan Smith
    Spyros Chalkias
    Giorgio Giannattasio
    Gabriel Lima
    Wanda Castro-Borrero
    Journal of Neurology, 2020, 267 : 2851 - 2864
  • [36] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [37] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James
    Harris, Sarah
    Riolo, Jon
    Cheng, Chun-Yen
    Reardon, Jennifer
    Thorpe, Andrew
    Cree, Bruce
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 354 - 354
  • [38] VISIONARY-MS Long-Term Extension: A Multicenter, Open-Label, Long-Term Extension Study of CNM-Au8 in Patients With Stable Relapsing Multiple Sclerosis
    Barnett, Michael
    Beadnall, Heidi
    Klistorner, Alexander
    Sergott, Robert
    Greenberg, Benjamin
    Rynders, Austin
    Ho, Karen
    Sepassi, Marjan
    Evan, Jacob
    Evan, Jeremy
    McBride, Ryan
    Hartford, Alan
    Hotchkin, Michael
    NEUROLOGY, 2024, 102 (12) : S12 - S13
  • [39] An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia
    Ohta, Hiroyoshi
    Oka, Hiroshi
    Usui, Chie
    Ohkura, Masayuki
    Suzuki, Makoto
    Nishioka, Kusuki
    MODERN RHEUMATOLOGY, 2013, 23 (06) : 1108 - 1115
  • [40] Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis
    Filippi, Massimo
    Henry, Roland
    Arnold, Douglas L.
    Granziera, Cristina
    Kappos, Ludwig
    Sheffield, James
    Chaudhry, Burhan
    Cheng, Chun-Yen
    Pachai, Chahin
    Silva, Diego
    Cree, Bruce
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 266 - 267
12345